Subcutaneous LMWH may be a safe and effective treatment for pulmonary embolism in hemodialysis patients without subsequent oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for PE in hemodialysis; single case leaves open need for prospective LMWH trials.
Low-molecular-weight heparin (LMWH) has been used in the prophylaxis and treatment of deep vein thrombosis. Data regarding the efficacy of this drug without subsequent use of oral anticoagulant in the treatment of pulmonary embolism is limited. Pulmonary embolism may complicate the use of central venous catheter in hemodialysis. We report a case of acute submassive pulmonary embolism complicating a central venous hemodialysis catheter in a dialysis patient. After the catheter was removed, the patient was treated successfully with subcutaneous injection of LMWH for three months. We conclude that LMWH is safe and effective for treatment of pulmonary embolism in patient on hemodialysis.
No takes yet. Share an insight, caveat, or question.
Szeto et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: